Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.08 – $0.24
13% from low
Exchange
OTC Link
OS
Borrow rate
0.58%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $118.0K | $168.3K | $1.6M | $3.3M | $4.0M | $16.8M | $25.5M | $25.5M |
| Cost of revenue | $172.7K | $76.1K | $2.1M | $437.1K | $2.9M | $10.1M | $12.6M | $12.6M |
| Gross profit | −$54.7K | $92.1K | −$570.1K | $2.8M | $1.1M | $6.7M | $12.9M | $12.8M |
| Gross margin | -46.4% | 54.8% | -36.3% | 86.6% | 27.6% | 39.7% | 50.7% | 50.4% |
| R&D | $456.6K | $1.2M | $376.3K | $304.3K | $276.9K | $330.7K | $178.2K | $256.2K |
| Operating income | −$9.2M | −$22.8M | −$18.5M | −$10.8M | −$10.6M | −$7.9M | −$4.7M | −$2.7M |
| EBITDA | −$8.3M | −$22.3M | −$17.4M | −$15.1M | −$12.2M | −$7.4M | −$2.4M | −$2.0M |
| Net income | −$7.1M | −$21.1M | −$32.9M | −$16.8M | −$14.7M | −$8.7M | −$3.6M | −$2.8M |
| Net margin | -6017.6% | -12524.1% | -2093.0% | -513.2% | -364.0% | -52.1% | -14.2% | -11.2% |
| EPS (diluted) | -0.45 | -1.05 | -1.12 | -0.41 | -0.25 | -0.10 | -0.04 | -0.02 |
Annual figures · source: Financial Modeling Prep
AVICANNA INC
No one on the platform currently holds AVCNF.
No tracked institution reports a position in AVCNF as of their last filing.
No one on the platform has traded AVCNF yet.
| $626130 |
| — |
| GBLPGlobal Pharmatech, Inc. | $0.08 | +0.00% | $33M | — |
| ISCNFIsracann Biosciences Inc. | $0.00 | +0.00% | $1760 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× sales vs its 1.3× historical median P/S.
Fair value ≈ $0.34 · price $0.10 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.